Stifel Nicolaus started coverage on shares of Illumina (NASDAQ:ILMN) in a research report released on Thursday, Briefing.com Automated Import reports. The firm issued a buy rating and a $345.00 target price on the life sciences company’s stock.

Several other brokerages have also issued reports on ILMN. Credit Suisse Group restated a buy rating and issued a $340.00 price objective on shares of Illumina in a report on Wednesday, July 31st. UBS Group boosted their price objective on shares of Illumina from $350.00 to $355.00 and gave the company a buy rating in a report on Tuesday, July 30th. ValuEngine lowered shares of Illumina from a buy rating to a hold rating in a report on Friday, October 25th. Canaccord Genuity lifted their target price on Illumina from $300.00 to $310.00 and gave the company a hold rating in a research report on Friday, October 25th. Finally, Piper Jaffray Companies dropped their target price on Illumina from $348.00 to $341.00 and set an overweight rating for the company in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $334.21.

ILMN traded up $0.69 on Thursday, hitting $306.67. The company had a trading volume of 996,500 shares, compared to its average volume of 1,030,535. The firm has a market cap of $43.87 billion, a P/E ratio of 53.61, a PEG ratio of 2.21 and a beta of 1.03. Illumina has a 1 year low of $263.30 and a 1 year high of $380.76. The company’s fifty day moving average price is $301.54 and its 200 day moving average price is $309.91. The company has a current ratio of 6.82, a quick ratio of 6.15 and a debt-to-equity ratio of 0.41.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 24th. The life sciences company reported $1.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.53. The firm had revenue of $907.00 million for the quarter, compared to analyst estimates of $872.65 million. Illumina had a net margin of 28.14% and a return on equity of 22.05%. Illumina’s revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.52 EPS. On average, analysts predict that Illumina will post 6.45 earnings per share for the current year.

In other news, SVP Mostafa Ronaghi sold 4,000 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $310.93, for a total transaction of $1,243,720.00. Following the completion of the transaction, the senior vice president now directly owns 80,585 shares of the company’s stock, valued at $25,056,294.05. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $283.41, for a total value of $935,253.00. Following the transaction, the director now directly owns 262,733 shares of the company’s stock, valued at $74,461,159.53. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 19,493 shares of company stock valued at $5,820,127. 0.38% of the stock is currently owned by corporate insiders.

Institutional investors have recently made changes to their positions in the company. Cim Investment Mangement Inc. grew its position in shares of Illumina by 3.9% during the second quarter. Cim Investment Mangement Inc. now owns 2,383 shares of the life sciences company’s stock worth $877,000 after buying an additional 89 shares in the last quarter. Copper Rock Capital Partners LLC acquired a new position in shares of Illumina during the second quarter worth about $10,888,000. Arjuna Capital acquired a new position in shares of Illumina during the second quarter worth about $269,000. Kornitzer Capital Management Inc. KS grew its position in shares of Illumina by 20.4% during the third quarter. Kornitzer Capital Management Inc. KS now owns 104,845 shares of the life sciences company’s stock worth $31,896,000 after buying an additional 17,796 shares in the last quarter. Finally, Handelsbanken Fonder AB grew its position in shares of Illumina by 45.6% during the second quarter. Handelsbanken Fonder AB now owns 60,653 shares of the life sciences company’s stock worth $22,329,000 after buying an additional 19,000 shares in the last quarter. 91.09% of the stock is owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Article: Hang Seng Index (HSI)

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.